novel treatment for neuroblastoma by live-attenuated poliovirus
Project/Area Number |
24591547
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Pediatrics
|
Research Institution | Mie University |
Principal Investigator |
TOYODA Hidemi 三重大学, 医学(系)研究科(研究院), 助教 (60525327)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
Keywords | 神経芽腫 / ポリオウイルス / oncolytic virotherapy |
Outline of Final Research Achievements |
The prognosis of neuroblastoma patients is poor. Thus, to develop a novel treatment is necessary. Our previous studies show that poliovirus has strong anti-neuroblastoma effects both in vitro and in vivo, and anti-neuroblastoma immune response was induced in neuroblastoma cured mice. In accordance with these findings, we started phase 1 clinical trial for relapse and refractory neuroblastoma patients. We have treated two relapsed neuroblastoma patients so far.
|
Report
(4 results)
Research Products
(5 results)
-
-
-
[Journal Article] Heterogeneity of neuroblastoma cell lines in insulin-like growth factor 1 receptor/Akt pathway-mediated cell proliferative responses.2013
Author(s)
Qi L, Toyoda H, Shankar V, Sakurai N, Amano K, Kihira K, Iwasa T, Deguchi T, Hori H, Azuma E, Gabazza EC, Komada Y
-
Journal Title
Cancer Science
Volume: 104
Issue: 9
Pages: 1162-1171
DOI
Related Report
Peer Reviewed
-
-